Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer

INTRODUCTION: Small cell lung cancer (SCLC) is a rapidly growing malignancy with early distant metastases. Up to 70% will develop brain metastases, and the poor prognosis of these patients has not changed considerably. The potential of checkpoint inhibitors (CPI) in treating recurrent (r/r) SCLC and...

Descripción completa

Detalles Bibliográficos
Autores principales: Althoff, Friederike C., Schäfer, Lisa V., Acker, Fabian, Aguinarte, Lukas, Heinzen, Sophie, Rost, Maximilian, Atmaca, Akin, Rosery, Vivian, Alt, Jürgen, Waller, Cornelius F., Reinmuth, Niels, Rohde, Gernot, Saalfeld, Felix C., Becker von Rose, Aaron, Möller, Miriam, Frost, Nikolaj, Sebastian, Martin, Stratmann, Jan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556470/
https://www.ncbi.nlm.nih.gov/pubmed/37810988
http://dx.doi.org/10.3389/fonc.2023.1273478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556470/
https://www.ncbi.nlm.nih.gov/pubmed/37810988
http://dx.doi.org/10.3389/fonc.2023.1273478

Ejemplares similares